HPLC
IndustriesPharma & Biopharma
ManufacturerThermo Fisher Scientific
Importance of the Topic
- The control of impurities in pharmaceutical compounds is critical to ensure drug safety and efficacy.
- Tranexamic acid is widely used as an antifibrinolytic agent, making reliable impurity testing essential for quality assurance.
Objectives and Study Overview
- Present a validated European Pharmacopeia (EP) method for identifying and quantifying impurities in tranexamic acid.
- Describe sample preparation, chromatographic conditions, and system suitability criteria.
- Demonstrate method performance through resolution and relative retention time measurements.
Methodology and Instrumentation
- Sample Preparation
- Test solution: 0.2 g tranexamic acid dissolved in water and diluted to 20 mL.
- Reference solution A: 5 mL test solution diluted to 100 mL, then 1 mL of that to 10 mL.
- Reference solution B: 20 mg tranexamic acid impurity C in water to 2 mL.
- Reference solution C: 12 mg impurity D to 100 mL, further dilutions to achieve final volume.
- Chromatographic Conditions
- Instrument: UltiMate 3000 LC.
- Column: Hypersil GOLD, 4.6×250 mm, 5 μm.
- Mobile phase: phosphate buffer with triethylamine and sodium lauryl sulfate, pH 2.5, mixed with methanol (60:40).
- Mode: isocratic, flow rate 0.9 mL/min, column temperature 25 °C.
- Detection: UV at 220 nm, injection volume 20 μL, run time 40 min.
- System Suitability Criteria
- Resolution between tranexamic acid and impurity C >= 1.5.
- Relative retention times (RRT) for impurities compared to the main peak.
Main Results and Discussion
- Resolution achieved between tranexamic acid and impurity C was 3.48, exceeding the EP requirement of 1.5.
- Observed RRT values:
- Impurity C: 1.15 (target ~1.1).
- Impurity D: 1.22 (target ~1.3).
- Impurity B: 1.54 (target ~1.5).
- Chromatograms confirmed clear separation of all identified impurities within a 40 min runtime.
- Method demonstrates high specificity, suitable for routine quality control.
Benefits and Practical Applications
- Provides a robust assay for impurity profiling in tranexamic acid batches.
- Supports regulatory compliance by meeting EP standards.
- Enables laboratories to reliably monitor critical impurities in production and stability studies.
Future Trends and Applications
- Integration with advanced detectors, such as mass spectrometry, for structural confirmation of unknown impurities.
- Adoption of shorter columns and faster gradients to reduce analysis time.
- Implementation of automated data processing and digital workflows for enhanced throughput.
Conclusion
- The EP method for tranexamic acid impurity testing is validated, specific, and reliable for quality control laboratories.
- System suitability results exceed required criteria, ensuring accurate detection and quantification of related substances.
- The approach supports pharmaceutical manufacturers in maintaining product purity and safety.
References
- No external references cited in this summary.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.